Literature DB >> 30566178

Risk Factors of Subsequent Primary Melanomas in Austria.

Christoph Müller1, Judith Wendt1, Sabine Rauscher1, Raute Sunder-Plassmann2, Erika Richtig3, Ingrid Fae4, Gottfried Fischer4, Ichiro Okamoto1.   

Abstract

Importance: Information on risk factors of subsequent melanomas would be helpful to identify patients at risk after the diagnosis of their first melanomas. Objective: To determine risk factors of subsequent melanomas. Design, Setting, and Participants: In this retrospective case-control study, 1648 participants with histologically verified cutaneous melanoma diagnosed from January 1, 1968, though March 16, 2015, were recruited from a tertiary referral center as part of the Molecular Markers of Melanoma study. CDKN2A was sequenced in 514 and MC1R in 953 participants. Data were analyzed from March 7, 2008, through March 25, 2015. Main Outcomes and Measures: Phenotypic traits and internal and external risk factors for the development of a second, third, or fourth melanoma.
Results: In total, 1648 patients (53.6% men; mean [SD] age, 54 [15] years) were enrolled, including 1349 with single and 299 with multiple primary melanoma. Mean (SD) age at recruitment was 57 (15) years for the single-melanoma and 62 (14) years for the multiple-melanoma groups. From the internal risk factors, family history (odds ratio [OR], 1.76; 95% CI, 1.22-2.55; P = .006), CDKN2A high-risk mutations (OR, 4.03; 95% CI, 1.28-12.70; P = .02), and high numbers of nevi as a phenotypic risk factor (ORs, 2.23 [95% CI, 1.56-3.28, P < .001] for 20-30 smaller nevi and 2.56 [95% CI, 1.50-4.36; P = .003] for 20-30 larger nevi) were significantly associated with the risk of developing a subsequent primary melanoma using multivariate logistic regression analysis. Nonmelanoma skin cancer (OR, 2.57; 95% CI, 1.84-3.58; P < .001) and signs of actinic skin damage, particularly on the back (ORs, 1.91 [95% CI, 1.12-3.25; P = .04] for freckling and 1.92 [95% CI, 1.29-3.08; P = .007] for solar lentigines), additionally increased risk of a subsequent melanoma. All those factors were also associated with an earlier development of the second melanoma. Patients with 3 melanomas developed their second melanoma earlier than patients with only 2 melanomas (mean [SD] age, 55 [15] years for those with 2 primary melanomas; 52 [15] years for those with 3 primary melanomas). Time spent outdoors, solarium use, outdoor occupation, and hair color had no significant associations in these models. Conclusions and Relevance: According to the results of this study, internal factors (family history and genetic variants), number of nevi, and actinic damage on the back are more relevant for the development of subsequent melanomas than skin phototype or hair color. Patients with many nevi were younger at the time of the diagnosis of their first melanoma. This finding could help to identify persons at increased risk of developing multiple primary melanomas.

Entities:  

Mesh:

Year:  2019        PMID: 30566178      PMCID: PMC6439543          DOI: 10.1001/jamadermatol.2018.4645

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  34 in total

Review 1.  Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.

Authors:  Marco Rastrelli; Saveria Tropea; Carlo Riccardo Rossi; Mauro Alaibac
Journal:  In Vivo       Date:  2014 Nov-Dec       Impact factor: 2.155

2.  Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom.

Authors:  Julia A Newton-Bishop; Yu-Mei Chang; Mark M Iles; John C Taylor; Bert Bakker; May Chan; Susan Leake; Birute Karpavicius; Sue Haynes; Elaine Fitzgibbon; Faye Elliott; Peter A Kanetsky; Mark Harland; Jennifer H Barrett; D Timothy Bishop
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

Review 3.  The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.

Authors:  Reinhard Dummer; Marco Siano; Robert E Hunger; Nicole Lindenblatt; Ralph Braun; Oliver Michielin; Daniela Mihic-Probst; Roger von Moos; Yousef Najafi; Merlin Guckenberger; Andreas Arnold
Journal:  Swiss Med Wkly       Date:  2016-02-22       Impact factor: 2.193

4.  Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma.

Authors:  J J Grob; J Gouvernet; D Aymar; A Mostaque; M H Romano; A M Collet; M C Noe; M P Diconstanzo; J J Bonerandi
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

5.  Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening.

Authors:  Joachim Hübner; Annika Waldmann; Nora Eisemann; Maria Noftz; Alan C Geller; Martin A Weinstock; Beate Volkmer; Rüdiger Greinert; Eckhard W Breitbart; Alexander Katalinic
Journal:  Eur J Cancer Prev       Date:  2018-11       Impact factor: 2.497

6.  Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology.

Authors:  Christopher K Bichakjian; Allan C Halpern; Timothy M Johnson; Antoinette Foote Hood; James M Grichnik; Susan M Swetter; Hensin Tsao; Victoria Holloway Barbosa; Tsu-Yi Chuang; Madeleine Duvic; Vincent C Ho; Arthur J Sober; Karl R Beutner; Reva Bhushan; Wendy Smith Begolka
Journal:  J Am Acad Dermatol       Date:  2011-08-25       Impact factor: 11.527

7.  Survival outcomes in patients with multiple primary melanomas.

Authors:  C J Rowe; M H Law; J M Palmer; S MacGregor; N K Hayward; K Khosrotehrani
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-04-10       Impact factor: 6.166

8.  Risk factors for second primary melanoma among Dutch patients with melanoma.

Authors:  M S Schuurman; A C de Waal; E J M Thijs; M M van Rossum; L A L M Kiemeney; K K H Aben
Journal:  Br J Dermatol       Date:  2017-03-10       Impact factor: 9.302

9.  Multiple primary melanomas.

Authors:  J J Stam-Posthuma; C van Duinen; E Scheffer; J Vink; W Bergman
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

10.  The importance of self-examination in the earliest diagnosis of multiple primary cutaneous melanomas: a report of 47 cases.

Authors:  A M Manganoni; C Farisoglio; G Tucci; F Facchetti; P G Calzavara Pinton
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-11       Impact factor: 6.166

View more
  6 in total

1.  Multiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital.

Authors:  Rodolfo David Palacios-Diaz; Blanca de Unamuno-Bustos; Carlos Abril-Pérez; Mónica Pozuelo-Ruiz; Javier Sánchez-Arraez; Ignacio Torres-Navarro; Rafael Botella-Estrada
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

2.  Incidence of Second Primary Melanoma in Cutaneous Melanoma Survivors.

Authors:  Alyssa A Wiener; Jessica R Schumacher; Jennifer M Racz; Sharon M Weber; Yaohui G Xu; Heather B Neuman
Journal:  Ann Surg Oncol       Date:  2022-05-03       Impact factor: 4.339

3.  A risk prediction model for the development of subsequent primary melanoma in a population-based cohort.

Authors:  A E Cust; C Badcock; J Smith; N E Thomas; L E Haydu; B K Armstrong; M H Law; J F Thompson; P A Kanetsky; C B Begg; Y Shi; A Kricker; I Orlow; A Sharma; S Yoo; S F Leong; M Berwick; D W Ollila; S Lo
Journal:  Br J Dermatol       Date:  2019-11-27       Impact factor: 9.302

4.  High-Throughput Sequencing Identifies 3 Novel Susceptibility Genes for Hereditary Melanoma.

Authors:  Catarina Campos; Sofia Fragoso; Rafael Luís; Filipe Pinto; Cheila Brito; Susana Esteves; Margarida Pataco; Sidónia Santos; Patrícia Machado; João B Vicente; Joaninha Costa Rosa; Branca M Cavaco; Cecília Moura; Marta Pojo
Journal:  Genes (Basel)       Date:  2020-04-08       Impact factor: 4.096

5.  Identification and Construction of a Predictive Immune-Related lncRNA Signature Model for Melanoma.

Authors:  Fang-Wei Li; Sheng-Kang Luo
Journal:  Int J Gen Med       Date:  2021-12-01

Review 6.  The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma.

Authors:  Piia Takabe; Hanna Siiskonen; Aino Rönkä; Kirsi Kainulainen; Sanna Pasonen-Seppänen
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.